Amgen urges US appeals court to rule Carefirst's US antitrust claims over Enbrel
( September 4, 2026, 22:31 GMT | Official Statement) -- MLex Summary: Amgen filed a reply brief urging a US appeals court to reverse an order that denied the dismissal of antitrust claims over Enbrel. “CareFirst’s alleged injury exists only because the [Patent and Trademark Office] issued patents after years of prosecution and a federal court, after a full trial, held those patents valid and infringed, rejected the argument that the 2004 license resulted in an unjustified extension of Amgen’s patent term, and enjoined Sandoz and Samsung from selling their biosimilars until the last patent expires in April 2029. Those simple facts defeat CareFirst’s antitrust claims for multiple independent reasons,” it said. See attached file. ...
Prepare for tomorrow’s regulatory change, today
MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.
Know what others in the room don’t, with features including:
- Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
- Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
- Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
- Curated case files bringing together news, analysis and source documents in a single timeline
Experience MLex today with a 14-day free trial.